Natalya Demakova

Ms. Natalya Demakova

Saint-Petersburg State Chemical-Pharmaceutical University
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MPMaria Povydysh
Maria Povydysh
MTMaria V. Titova
Maria V. Titova
IIIgor M. Ivanov
Igor M. Ivanov
AKAndrey G. Klushin
Andrey G. Klushin
DKDmitry V. Kochkin
Dmitry V. Kochkin
ANAlexander Mihailovich Nosov
Alexander Mihailovich Nosov
In the present study, we explored the therapeutic potential of bioreactor-grown cell cultures of the medicinal plant species Dioscorea deltoidea, Tribulus terrestris and Panax japonicus to treat carbohydrate metabolism disorders (CMDs) in laboratory rats. In the adrenaline model of hyperglycemia, aqueous suspensions of cell biomass pre-administered at a dose of 100 mg dry biomass/kg significantly reduced glucose level in animal blood 1–2.5 h (D. deltoidea and T. terrestris) or 1 h (P. japonicus) after adrenaline hydrochloride administration. In a streptozotocin-induced model of type 2 diabetes mellitus, the cell biomass of D. deltoidea and T. terrestris acted towards normalization of carbohydrate and lipid metabolism, as evidenced by a significant reduction of daily diuresis (by 39–57%), blood-glucose level (by 46–51%), blood content in urine (by 78–80%) and total cholesterol (25–36%) compared to animals without treatment. Bioactive secondary metabolites identified in the cell cultures and potentially responsible for their actions were deltoside, 25(S)-protodioscin and protodioscin in D. deltoidea; furostanol-type steroidal glycosides and quinic acid derivatives in T. terrestris; and ginsenosides and malonyl-ginsenosides in P. japonicus. These results evidenced for high potential of bioreactor-grown cell suspensions of these species for prevention and treatment of CMD, which requires further investigation.

1 January 2021 in Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science)
Verified
Journal Article
Closed access
NDNatalya Demakova
Natalya Demakova
MKMarina Krasnova
Marina Krasnova
GPG.A. Plisko
G.A. Plisko
ESE.D. Semivelichenko
E.D. Semivelichenko
DIDmitriy Ivkin
Dmitriy Ivkin
SOSergey Okovityi
Sergey Okovityi

1 January 2021 in Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science)
Verified
Journal Article
Closed access
GPG.A. Plisko
G.A. Plisko
UNU.V. Nogaeva
U.V. Nogaeva
ESE.D. Semivelichenko
E.D. Semivelichenko
DIDmitriy Ivkin
Dmitriy Ivkin
ITI.A. Titovich
I.A. Titovich
AIA.S. Ivkina
A.S. Ivkina

1 January 2021 in Cardiology: News, Opinions, Training
Verified
Journal Article
Closed access
AFAcademician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Health of the Russian Federation
Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Health of the Russian Federation
AKA.N. Kulikov
A.N. Kulikov
MKMarina Krasnova
Marina Krasnova
SUSaint-Petersburg State Chemical and Pharmaceutical University
Saint-Petersburg State Chemical and Pharmaceutical University
DIDmitriy Ivkin
Dmitriy Ivkin
NDNatalya Demakova
Natalya Demakova
Эффективность эмпаглифлозина при экспериментальной хронической сердечной недостаточности в условиях нормогликемии

1 January 2021 in Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science)
Verified
Journal Article
Closed access
NDNatalya Demakova
Natalya Demakova
MKM.A. Korotyhina
M.A. Korotyhina
YSYuriy Sysoev
Yuriy Sysoev
AKA.V. Karshin
A.V. Karshin
NAN.A. Anisimova
N.A. Anisimova
DIDmitriy Ivkin
Dmitriy Ivkin